TLR3 activation enhances abscopal effect of radiotherapy in HCC by promoting tumor ferroptosis.
Liman QiuHongbing JiKai WangWenhan LiuQizhen HuangXinting PanHonghao YeZhenli LiGeng ChenXiaohua XingXiuqing DongRuijing TangHaipo XuJingfeng LiuZhixiong CaiXiao-Long LiuPublished in: EMBO molecular medicine (2024)
Radiotherapy (RT) has been reported to induce abscopal effect in advanced hepatocellular carcinoma (HCC), but such phenomenon was only observed in sporadic cases. Here, we demonstrated that subcutaneous administration of Toll-like receptor 3 (TLR3) agonist poly(I:C) could strengthen the abscopal effect during RT through activating tumor cell ferroptosis signals in bilateral HCC subcutaneous tumor mouse models, which could be significantly abolished by TLR3 knock-out or ferroptosis inhibitor ferrostatin-1. Moreover, poly(I:C) could promote the presentation of tumor neoantigens by dendritic cells to enhance the recruitment of activated CD8 + T cells into distant tumor tissues for inducing tumor cell ferroptosis during RT treatment. Finally, the safety and feasibility of combining poly(I:C) with RT for treating advanced HCC patients were further verified in a prospective clinical trial. Thus, enhancing TLR3 signaling activation during RT could provide a novel strategy for strengthening abscopal effect to improve the clinical benefits of advanced HCC patients.
Keyphrases
- toll like receptor
- inflammatory response
- immune response
- end stage renal disease
- cell death
- clinical trial
- dendritic cells
- chronic kidney disease
- nuclear factor
- ejection fraction
- early stage
- newly diagnosed
- single cell
- prognostic factors
- randomized controlled trial
- cell therapy
- peritoneal dialysis
- gene expression
- patient reported outcomes
- signaling pathway
- case report
- replacement therapy
- phase ii